Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that positive findings have been seen in a total of six out of eight Intermediate Size Patient Population Expanded Access (EA) patients, which have shown improvements in fatigue scores measured by the Modified Fatigue Impact Scale (MFIS).
The clinical-stage biopharmaceutical company said PET scan findings showing a reduction in microglial activation were also seen in the six patients with MFIS score improvement at the three-month evaluation period.
"We’ve seen continued clinical and qualitative PET scan improvement over time in patients with na-SPMS where intranasal foralumab targets inflammation in the brain," Tiziana Life Sciences acting CEO Gabriele Cerrone said in a statement.
"It is my expectation that we will rapidly progress our ongoing Phase 2 trial of intranasal foralumab, given the encouraging results seen so far under the EA IND," Cerrone added.
Tiziana noted that PET scan findings for two additional EA patients (10 total) are planned to be available in late January.
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy.